Shi Y, et al. - By searching databases of PubMed, MEDLINE, EMBASE, Web of Science and Cochrane Library through June 2018, researchers conducted a systematic review and meta-analysis to evaluate the differences in infection rates between rituximab (RTX) and non-RTX treatment in rheumatoid arthritis (RA) patients. The inclusion criteria were met by a total of 11 articles, including 9,502 patients. The authors concluded that RTX therapy has no additional risk of infection over non-RTX therapy, in patients with RA.